Change of coagulation parameters after double plateletpheresis

Yılmaz, Mustafa; Dikmen, Tamer; Sönmez, Mehmet; Akdoğan, Elif; Durmuş, Ahmet; Omay, Serdar Bedii; Ovalı, Ercüment

doi:10.1016/j.transci.2007.07.004

Cited by 13 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At day 2, FVIII and vWF activity as well as vWF antigen showed a weak and not significant increase accompanied by a slight decrease of aPTT compared to levels before apheresis. In accordance with others [9–11, 13, 15], the observed changes of our pro‐thrombotic markers revealed no hint of a hypercoagulable state.…”

Section: Discussionsupporting

confidence: 92%

“…In a recent study, 33·9% of thrombapheresis donors were shown to have depleted iron stores compared to 3·1% of controls [8]. Putative alterations in the coagulation system due to apheresis have been investigated [9–15] whereby only two studies identified a potential pro‐thrombotic situation [12, 14]. One study reported that several days after apheresis activated platelets (PLTs) were detectable in donors [16], but this could not be confirmed by another study [17].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Influence of multicomponent apheresis on donors’ haematological and coagulation parameters, iron storage and platelet function

et al. 2012

View full text Add to dashboard Cite

Background and Objectives Multicomponent collection (MCC) enables production and processing of various blood components during one apheresis session. In this prospective crossover study, the effects of donating platelets (PLTs) and packed red blood cells (PRBCs) on donor’s blood cell count, coagulation, PLT function and iron state were analysed. Materials and Methods Forty‐eight MCCs were performed using two different cell separators (Fenwal Amicus®, CaridianBCT Trima Accel®). Two units of platelet concentrates and one unit of PRBCs were collected during each session. Full blood cell count and iron status were obtained on day 0 before and after apheresis, day 2, day 14 and day 42. PLT function was analysed by aggregometry and rotation thromboelastometry in parallel with coagulation tests before and after MCC and at day 2. Results Multicomponent collection was well tolerated without adverse side effects. Blood cell count and iron parameters declined and most of them (haemoglobin, haematocrit, transferrin, transferrin saturation and ferritin) were significantly below baseline values until at least day 42 after donation. Absent iron stores were seen in 31·3% of the donors. In contrast, PLTs significantly exceeded pre‐donation values after 14 days and remained significantly increased for 42 days. After 2 days, coagulation parameters were only slightly (P > 0·05) altered, whereas PLT function was significantly reduced. Conclusion Multicomponent collection is an obviously safe procedure; however, the significant long‐term impact on the donor’s blood count and iron store, as well as impaired PLT function, has to be considered in regard to donor safety.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Influence of multicomponent apheresis on donors’ haematological and coagulation parameters, iron storage and platelet function

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Yilmaz et al. using similar method showed no significant difference in this parameter 9 . PT and APTT prolongations in patients are usually associated with risk of bleeding, except those with lupus anticoagulant where patients are usually asymptomatic or showing thromboembolic manifestations.…”

Section: Discussionmentioning

confidence: 90%

“…Based on the literature review, we could not find current articles related to this study. Studies on the effects of plateletpheresis on platelet indices and blood coagulation parameters among regular plateletpheresis donors were found 8, 9. However, these studies addressed coagulation parameters immediately post plateletpheresis donation.…”

Section: Introductionmentioning

confidence: 99%

Haemostatic parameters, platelet activation markers, and platelet indices among regular plateletpheresis donors

Tuan

Hock

Abdullah

2018

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

Objective Plateletpheresis is generally a safe procedure for platelet donation. Studies on the effects of haemostatic parameters and possible association between automated plateletpheresis and hypercoagulable state are limited. Hence, this study aimed to investigate the effects of plateletpheresis on regular donors using haemostatic parameters, i.e. natural anticoagulant proteins, platelet indices, and platelet activation markers. Methods A total of 139 participants (plateletpheresis donors and normal controls) were recruited and divided into two groups: Group 1 participants who underwent tests for haemostatic and platelet indices and Group 2 participants who underwent tests for platelet activation markers using CD62P and PAC-1 monoclonal antibodies. Results A significant mild shortening of prothrombin time and platelet activation were demonstrated (by increased CD62P and PAC-1 markers) among regular plateletpheresis donors as compared to healthy controls. The current pre-donation platelet count of plateletpheresis donors was significantly lower than their mean baseline platelet count obtained before their first plateletpheresis procedure. However, no significant differences were observed for the other platelet parameters (platelet count, mean platelet volume, platelet distribution width, activated partial thromboplastin time, protein C, protein S, antithrombin, and von Willebrand Factor antigen) between plateletpheresis donors and healthy controls. Conclusion This study concludes that regular plateletpheresis is a safe procedure. A possibility of mild platelet activation among regular donors requires further confirmation. However, pre-analytical platelet and FVII activations could occur in vitro contributing to these findings.

show abstract

“…Plateletpheresis has effects on coagulation parameters by decreasing pro-thrombotic FVIII, fibrinogen, anti-thrombin, protein C and protein S levels, albeit maintaining them within acceptable ranges [50, 51]. While von-Willebrand multimeric structures remain unchanged, von Willebrand levels can drop by up to 15% as a result of dilution and replacement of plasma by anticoagulant during apheresis [52].…”

Section: Discussionmentioning

confidence: 99%

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

et al. 2017

View full text Add to dashboard Cite

Extreme thrombocytosis induces an acquired thrombotic-hemorrhagic diathesis, and left uncontrolled is a harbinger of potentially fatal vascular complications. Currently, cytoreduction with medical therapy remains the mainstay of hyperthrombocytosis management. However, it offers a less-than-ideal option in situations where a rapid reduction in platelets is urgently needed, as in the presence of vital end-organ ischemia or to ameliorate of life-threatening hemorrhage. The role of thrombocytapheresis, or plateletpheresis, in hyperthrombocytosis has become increasingly obsolete given the proactive titration of cytoreductive therapies and early identification and correction of reversible causes of reactive thrombocytosis. Despite its narrowed indications, plateletpheresis continues to offer a valuable temporizing measure in platelet count reduction before cytoreductive agents exert their maximal effect. In this context, it is important for the treating physician to be aware of the symptoms and risks associated with hyperthrombocytosis to inform best clinical practices. In this review, we discuss the role of plateletpheresis in the modern-day management of hyperthrombocytosis in patients with myeloproliferative neoplasms through a case based review of the literature. It becomes apparent throughout the discussion that the decision to perform plateletpheresis should be individualized based upon the clinical scenario, degree of thrombocytosis, available infrastructure and every patient’s risk profile.

show abstract

Change of coagulation parameters after double plateletpheresis

Cited by 13 publications

References 9 publications

Influence of multicomponent apheresis on donors’ haematological and coagulation parameters, iron storage and platelet function

Influence of multicomponent apheresis on donors’ haematological and coagulation parameters, iron storage and platelet function

Haemostatic parameters, platelet activation markers, and platelet indices among regular plateletpheresis donors

The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review

Contact Info

Product

Resources

About